Section Arrow
Quote
LQDA.NASDAQ
- Liquidia Corp
Quotes are at least 15-min delayed:2026/05/22 06:49 EDT
Pre Market
Last
 62.09
+0.12 (+0.19%)
Bid
60.78
Ask
63.42
High 62.56 
Low 60.68 
Volume 263 
Regular Hours (Closed)
Last
 61.97
+0.2 (+0.32%)
Day High 
62.3 
Prev. Close
61.77 
1-M High
62.17 
Volume 
1.20M 
Bid
60.78
Ask
63.42
Day Low
59.95 
Open
61.08 
1-M Low
35.8 
Market Cap 
5.49B 
Currency 美元 
P/E 364.53 
%Yield -- 
10-SMA 54.69 
20-SMA 46.64 
50-SMA 41.15 
52-W High 62.17 
52-W Low 11.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.17/3.11
Enterprise Value
5.63B
Balance Sheet
Book Value Per Share
1.22
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
158.32M
Operating Revenue Per Share
0.21
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SBFMSunshine Biopharma Inc0.5164+0.1491+40.59%-- 
Pre Market 0.4658 -0.0506 -9.80%
HIMSHims & Hers Health24.01+0.97+4.21%-- 
Pre Market 23.89 -0.12 -0.50%
CGCCanopy Growth Corp1.07+0.04+3.88%-- 
Pre Market 1.06 -0.01 -0.93%
ZTSZOETIS80.07+0.36+0.45%13.13PE
Pre Market 80.21 +0.14 +0.17%
VTRSViatris16.46-0.13-0.78%-- 
Pre Market 16.31 -0.03 -0.18%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.